DRG 233 Overview

DRG 233 covers hospital admissions for coronary artery bypass grafting performed with concurrent cardiac catheterization or open ablation procedures when a Major Complication or Comorbidity is present. It includes complex cardiac surgical care where significant additional resources are used due to the severity of the patients condition. This Diagnosis-Related Group is important for Medicare payment because the presence of a Major Complication or Comorbidity increases the relative weight and expected resource use for the inpatient stay. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and thereby affect reimbursement.

National payer benchmarks for DRG 233 span from roughly $370 up to $270K across payers, with payer medians clustered between $64K and $120K depending on carrier. The widest spread between minimum and maximum observations is seen in Anthem’s data (from $390 to $270K). See the table and chart below for payer-specific quartiles and distributions.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 233. These figures reflect payments and charges submitted to Medicare for the reporting year.

• Acute perioperative intervention trials: randomized or controlled studies testing intraoperative and immediate postoperative strategies to reduce complications for patients undergoing coronary artery bypass grafting (CABG) performed with concurrent cardiac catheterization or open ablation, such as protocols for myocardial protection, bleeding management, or perioperative anticoagulation strategies. The patient population includes high-acuity surgical patients with multivessel coronary disease and often concomitant arrhythmia procedures or invasive diagnostics, where interventions are targeted to reduce mortality, stroke, reoperation for bleeding, and ICU stay. This research is relevant to providers and payers because improvements in perioperative complication rates and shorter critical care utilization directly affect short-term outcomes, readmission risk, and inpatient costs associated with this high-cost DRG.
• Comparative effectiveness trials of revascularization and rhythm-control strategies: pragmatic studies comparing clinical pathways (for example, CABG plus staged versus simultaneous catheter-based coronary interventions, or CABG combined with surgical ablation versus CABG alone in patients with concomitant atrial fibrillation) that evaluate major cardiovascular outcomes, functional status, and resource utilization. These trials enroll patients with multivessel coronary disease who require bypass and have coexisting arrhythmia or who undergo diagnostic catheterization prompting hybrid procedures; the goal is to define which approach yields the best balance of survival, quality of life, and healthcare utilization. Results inform clinicians and payers about which strategies provide superior long-term value, helping guide guideline-based care, reimbursement policies, and bundled payment models for complex cardiac surgical episodes.
• Post-discharge outcomes and systems-of-care studies: cohort studies and implementation research assessing post-acute recovery, rehabilitation needs, readmission drivers, and long-term graft patency or arrhythmia recurrence after CABG with catheterization or open ablation, including evaluation of care transitions, adherence to secondary prevention, and remote monitoring interventions. The studied population includes survivors after hospitalization who are at elevated risk for readmission, medication nonadherence, wound complications, or recurrent ischemic or arrhythmic events; research measures functional recovery, quality of life, and costs over months to years. These data are critical for providers and payers to design targeted discharge planning, allocate outpatient resources, and optimize value-based payment approaches by reducing preventable readmissions and long-term complications associated with this DRG.